ASCO 2023 | The role of the multidisciplinary team in providing adequate diagnosis & treatment for BPDCN
Claudio Cerchione
• 2 Jun 2023
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, comments on the role of the multidisciplinary team in providing an accurate diagnosis, treatment, and care for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), discussing the benefits of tagraxofusp and highlighting the importance of collecting molecular data to improve patient outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
